NCT04661137 - A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 16, 2021

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions

Multiple Myeloma

Interventions

DRUG

Selinexor 60 MG

Selinexor 60 mg PO on days 1, 8 and 15

DRUG

Selinexor 80 MG

Selinexor 80 mg PO on days 1, 8 and 15

DRUG

Selinexor 100 MG

Selinexor 100 mg PO on days 1, 8, 15 and 22

DRUG

Carfilzomib

56 mg/m2 IV on days 1, 8 and 15

DRUG

Pomalidomide

4 mg PO daily for 21 days

DRUG

Daratumumab

16 mg/kg IV days 1, 8, 15 and 22 for cycles 1-2; days 1 and 15 for cycles 3-6; day 1 for cycle 7 and on

DRUG

Dexamethasone

20 mg if ≥ 75 years old and 40 mg if \< 75 years old on days 1, 8, 15 and 22

Trial Locations (2)

Lombardi Comprehensive Cancer Center, Washington D.C.

John Theurer Cancer Center, Hackensack